Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Coronary Syndrome, Coronary Bypass Stenosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Norway, Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)
Primary outcome measures
- Graft patency after CABG [Time frame: 12-36 months]
Secondary outcome measures (5)
- Graft patency after CABG - PP analysis [Time frame: 12-36 months]
- Graft patency after CABG [Time frame: 12-36 months]
- Graft patency after CABG [Time frame: 12-36 months]
- Graft patency after CABG [Time frame: 12-36 months]
- Graft patency after CABG [Time frame: 12-36 months]
Eligibility criteria
Inclusion criteria
- Previously included in TACSI-trial
Exclusion criteria
- Highly irregular heart rhythm (i.e. atrial fibrillation)
- Chronic kidney disease with estimated glomerular filtration rate (eGFR) <45ml/min/1,73m2
- Body weight >120 kg
- Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents
- Not able to communicate
- Not willing to participate
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Sweden · 4 centers
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicin — Gothenburg
- Dep of Vascular and Thoracic Surgery — Örebro
- Department of Cardiothoracic Surgery Karolinska University Hospital — Stockholm
- University Hospital Linköping — Linköping
Norway · 2 centers
- Department of Heart Disease, Haukeland University Hospital — Bergen
- St Olavs University Hospital — Trondheim
Identifiers
NCT: NCT04783701 · CoCAP